Kane Biotech to Present at The MicroCap Conference
WINNIPEG, Manitoba, April 05, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will present at the MicroCap Conference being held in New York, NY from April 9-10, 2018. Mark Ahrens-Townsend, Chief Executive Officer of Kane Biotech, will be giving a presentation and meeting with investors attending the conference.
Event: The MicroCap Conference
Date: Monday, April 9, 2018
Time: 12:30pm Eastern Time
Location: Track 1, The Essex House, New York, NY
Investors interested in meeting with Kane Biotech should contact Tirth Patel, VP Investor Relations at firstname.lastname@example.org.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane™ are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF.”
For more information, please visit www.kanebiotech.com or contact:
President & CEO
Kane Biotech Inc.
+1 (204) 477-7592
Vice President - Investor Relations
+1 (646) 653-7035
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Released April 5, 2018